Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mifepristone + fluvastatin is a combination of two small molecule drugs, each with distinct mechanisms and indications. **Mifepristone** is a synthetic steroid that acts as an antagonist at both the progesterone receptor and the glucocorticoid receptor. It is primarily used for medical termination of intrauterine pregnancy (in combination with misoprostol) by blocking progesterone, which is necessary to maintain pregnancy. It also blocks cortisol action at the glucocorticoid receptor, making it useful in controlling hyperglycemia secondary to hypercortisolism in Cushing's syndrome patients who have failed or are not candidates for surgery[1][2][3][4][5][6]. **Fluvastatin** is a fully synthetic statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By lowering plasma cholesterol levels, it reduces cardiovascular risk including myocardial infarction and stroke[8]. There are no known approved or investigational uses for this specific drug combination; each agent retains its individual primary indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mifepristone + fluvastatin.